Conflicts of interest: J-H. R., V. P. S., Y. W. and K. E. L. have no conflict of interest. N. A. is an employee of SITS International, which received a grant from Boehringer Ingelheim and Ferrer for conducting the SITS-MOST and SITS-ISTR studies. E. B. is an employee of Boehringer Ingelheim GmbH, Germany. K. H. is an employee of Boehringer Ingelheim AB, Sweden. N. W. has received expenses from Boehringer Ingelheim for his role as member of the Steering Committee of the ECASS III trial, has served as a consultant to Thrombogenics as chairman of the DSMB, and has also received lecture fees from Boehringer Ingelheim and from Ferrer. SITS International (chaired by N. W.) received grants from Boehringer Ingelheim and from Ferrer for SITS-MOST and SITS-ISTR. N. W.'s institution has also received grant support toward administrative expenses for coordination of the ECASS III trial.
Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW)
Article first published online: 18 SEP 2012
© 2012 The Authors. International Journal of Stroke © 2012 World Stroke Organization
International Journal of Stroke
How to Cite
Rha, J.-H., Shrivastava, V. P., Wang, Y., Lee, K. E., Ahmed, N., Bluhmki, E., Hermansson, K., Wahlgren, N. and for the SITS Investigators (2012), Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW). International Journal of Stroke. doi: 10.1111/j.1747-4949.2012.00895.x
Role of funding body: The study protocol was drafted by SITS and developed in close collaboration between SITS and Boehringer Ingelheim. All data collection and analyses were performed independently by SITS except for analysis of the rates of events in the database of pooled randomized controlled trials, which were performed by Erich Bluhmki. Boehringer Ingelheim was responsible for reporting of serious adverse drug reactions to regulatory authorities.
- Article first published online: 18 SEP 2012
- Boehringer Ingelheim
Options for accessing this content:
- If you have access to this content through a society membership, please first log in to your society website.
- If you would like institutional access to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions and you will be able to log in to access content. Some users may also log in directly via OpenAthens.
Please note that there are currently a number of duplicate entries in the list of institutions. We are actively working on fixing this issue and apologize for any inconvenience caused.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.